INmune Bio Announces Positive Phase 2 MINDFuL Trial Results for XPro™ in Early Alzheimer’s Disease with Inflammation

Reuters09-29

INmune Bio Announces Positive Phase 2 MINDFuL Trial Results for XPro™ in Early Alzheimer's Disease with Inflammation

INmune Bio Inc. has announced the submission of results from its Phase 2 MINDFuL trial evaluating XPro™, a selective soluble TNF neutralizer, in patients with early Alzheimer's disease and inflammation. The manuscript, titled "XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer's Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial," has been submitted for peer review to npj Dementia, a Nature Portfolio journal. According to the company, the trial demonstrated positive trends in cognitive, neuropsychiatric, and biological endpoints in a prespecified subgroup of patients with both amyloid pathology and a high inflammatory burden. While the primary endpoint was not met in the overall population, a promising signal was observed in this biomarker-enriched ADi subgroup. The results have been made available as a preprint on medRxiv and are pending further peer-reviewed publication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536487-en) on September 29, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2571338132?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-29 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571338132","market":"fut","top_or_hot":-1,"title":"INmune Bio Announces Positive Phase 2 MINDFuL Trial Results for XPro™ in Early Alzheimer’s Disease with Inflammation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      INmune Bio Announces Positive Phase 2 MINDFuL Trial Results for XPro™ in Early Alzheimer's Disease with Inflammation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/INMB\">INmune Bio Inc</a>. has announced the submission of results from its Phase 2 MINDFuL trial evaluating XPro™, a selective soluble TNF neutralizer, in patients with early Alzheimer's disease and inflammation. The manuscript, titled \"XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer's Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial,\" has been submitted for peer review to npj Dementia, a Nature Portfolio journal. According to the company, the trial demonstrated positive trends in cognitive, neuropsychiatric, and biological endpoints in a prespecified subgroup of patients with both amyloid pathology and a high inflammatory burden. While the primary endpoint was not met in the overall population, a promising signal was observed in this biomarker-enriched ADi subgroup. The results have been made available as a preprint on medRxiv and are pending further peer-reviewed publication.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536487-en) on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INmune Bio Announces Positive Phase 2 MINDFuL Trial Results for XPro™ in Early Alzheimer’s Disease with Inflammation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINmune Bio Announces Positive Phase 2 MINDFuL Trial Results for XPro™ in Early Alzheimer’s Disease with Inflammation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-29 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      INmune Bio Announces Positive Phase 2 MINDFuL Trial Results for XPro™ in Early Alzheimer's Disease with Inflammation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/INMB\">INmune Bio Inc</a>. has announced the submission of results from its Phase 2 MINDFuL trial evaluating XPro™, a selective soluble TNF neutralizer, in patients with early Alzheimer's disease and inflammation. The manuscript, titled \"XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer's Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial,\" has been submitted for peer review to npj Dementia, a Nature Portfolio journal. According to the company, the trial demonstrated positive trends in cognitive, neuropsychiatric, and biological endpoints in a prespecified subgroup of patients with both amyloid pathology and a high inflammatory burden. While the primary endpoint was not met in the overall population, a promising signal was observed in this biomarker-enriched ADi subgroup. The results have been made available as a preprint on medRxiv and are pending further peer-reviewed publication.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536487-en) on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDLJN7bc:1","article_id":"2571338132","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571338132","pubTimestamp":1759147248,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"INmune Bio Inc. has announced the submission of results from its Phase 2 MINDFuL trial evaluating XPro, a selective soluble TNF neutralizer, in patients with early Alzheimer's disease and inflammation. The manuscript, titled \"XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer's Disease with Inflammation : Results from the Phase 2 MINDFuL Trial,\" has been submitted for peer review to npj Dementia, a Nature Portfolio journal. According to the company, the trial demonstrated positive trends in cognitive, neuropsychiatric, and biological endpoints in a prespecified subgroup of patients with both amyloid pathology and a high inflammatory burden. While the primary endpoint was not met in the overall population, a promising signal was observed in this biomarker-enriched ADi subgroup. The results have been made available as a preprint on medRxiv and are pending further peer-reviewed publication.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","BK4112":"金融交易所和数据","BK4139":"生物科技","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","INMB":"INmune Bio Inc","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股"},"translate_title":"INmune Bio宣布XPro 2期正念试验结果积极™早期阿尔茨海默病伴炎症","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INMB":0.9,"NDAQ":0.9},"content_text":"INmune Bio Announces Positive Phase 2 MINDFuL Trial Results for XPro™ in Early Alzheimer's Disease with Inflammation\n    \n\nINmune Bio Inc. has announced the submission of results from its Phase 2 MINDFuL trial evaluating XPro™, a selective soluble TNF neutralizer, in patients with early Alzheimer's disease and inflammation. The manuscript, titled \"XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer's Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial,\" has been submitted for peer review to npj Dementia, a Nature Portfolio journal. According to the company, the trial demonstrated positive trends in cognitive, neuropsychiatric, and biological endpoints in a prespecified subgroup of patients with both amyloid pathology and a high inflammatory burden. While the primary endpoint was not met in the overall population, a promising signal was observed in this biomarker-enriched ADi subgroup. The results have been made available as a preprint on medRxiv and are pending further peer-reviewed publication.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536487-en) on September 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2571338132","isCrawlerRequest":true}